全文获取类型
收费全文 | 1802篇 |
免费 | 137篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 46篇 |
妇产科学 | 26篇 |
基础医学 | 234篇 |
口腔科学 | 34篇 |
临床医学 | 275篇 |
内科学 | 341篇 |
皮肤病学 | 34篇 |
神经病学 | 112篇 |
特种医学 | 293篇 |
外科学 | 162篇 |
综合类 | 32篇 |
预防医学 | 119篇 |
眼科学 | 48篇 |
药学 | 85篇 |
中国医学 | 1篇 |
肿瘤学 | 106篇 |
出版年
2023年 | 8篇 |
2022年 | 9篇 |
2021年 | 29篇 |
2020年 | 14篇 |
2019年 | 10篇 |
2018年 | 26篇 |
2017年 | 24篇 |
2016年 | 31篇 |
2015年 | 22篇 |
2014年 | 52篇 |
2013年 | 64篇 |
2012年 | 61篇 |
2011年 | 62篇 |
2010年 | 65篇 |
2009年 | 72篇 |
2008年 | 75篇 |
2007年 | 69篇 |
2006年 | 66篇 |
2005年 | 56篇 |
2004年 | 40篇 |
2003年 | 57篇 |
2002年 | 52篇 |
2001年 | 49篇 |
2000年 | 51篇 |
1999年 | 39篇 |
1998年 | 63篇 |
1997年 | 55篇 |
1996年 | 55篇 |
1995年 | 47篇 |
1994年 | 34篇 |
1993年 | 29篇 |
1992年 | 30篇 |
1991年 | 37篇 |
1990年 | 26篇 |
1989年 | 53篇 |
1988年 | 42篇 |
1987年 | 38篇 |
1986年 | 31篇 |
1985年 | 36篇 |
1984年 | 21篇 |
1983年 | 35篇 |
1982年 | 32篇 |
1981年 | 25篇 |
1980年 | 24篇 |
1979年 | 17篇 |
1978年 | 21篇 |
1977年 | 23篇 |
1976年 | 14篇 |
1975年 | 12篇 |
1974年 | 12篇 |
排序方式: 共有1963条查询结果,搜索用时 15 毫秒
51.
52.
Zeeshan H. Syedain Lee A. Meier Jay M. Reimer Robert T. Tranquillo 《Annals of biomedical engineering》2013,41(12):2645-2654
A novel tissue-engineered heart valve (TEHV) was fabricated from a decellularized tissue tube mounted on a frame with three struts, which upon back-pressure cause the tube to collapse into three coapting “leaflets.” The tissue was completely biological, fabricated from ovine fibroblasts dispersed within a fibrin gel, compacted into a circumferentially aligned tube on a mandrel, and matured using a bioreactor system that applied cyclic distension. Following decellularization, the resulting tissue possessed tensile mechanical properties, mechanical anisotropy, and collagen content that were comparable to native pulmonary valve leaflets. When mounted on a custom frame and tested within a pulse duplicator system, the tubular TEHV displayed excellent function under both aortic and pulmonary conditions, with minimal regurgitant fractions and transvalvular pressure gradients at peak systole, as well as well as effective orifice areas exceeding those of current commercially available valve replacements. Short-term fatigue testing of one million cycles with pulmonary pressure gradients was conducted without significant change in mechanical properties and no observable macroscopic tissue deterioration. This study presents an attractive potential alternative to current tissue valve replacements due to its avoidance of chemical fixation and utilization of a tissue conducive to recellularization by host cell infiltration. 相似文献
53.
Ramnath Santosh Ramanathan Dolora Wisco Daniel Vela-Duarte Atif Zafar Ather Taqui Stacey Winners A Blake Buletko Fredrick Hustey Andrew Reimer Andrew Russman Ken Uchino M Shazam Hussain 《Journal of stroke and cerebrovascular diseases》2021,30(7):105801
ObjectivesMobile stroke unit (MSU) has been shown to rapidly provide pre-hospital thrombolysis in acute ischemic stroke (AIS). MSU encounters neurological disorders other than AIS that require emergent treatment.Methods/MaterialsWe obtained pre-hospital diagnosis and treatment data from the prospectively collected dataset on 221 consecutive MSU encounters. Based on initial clinical evaluation and neuroimaging obtained on MSU, the diagnosis of AIS (definite, probable, and possible AIS, transient ischemic attack), intracranial hemorrhage, and likely stroke mimics was made.ResultsFrom July 2014 to April 2015, 221 patients were treated on MSU. 78 (35%) patients had initial clinical diagnosis of definite/probable AIS or TIA, 69 (31%) were diagnosed as possible AIS or TIA, 15 (7%) had intracranial hemorrhage while 59 patients (27%) were diagnosed as likely stroke mimics. Stroke mimics encountered included 13 (6%) metabolic encephalopathy, 11 (5%) seizures, 9 (4%) migraines, 3 (1%) substance abuse, 2 (1%) CNS tumor, 3 (1%) infectious etiology and 3 (1%) hypoglycemia. Fifty-four (24%) patients received non-thrombolytic treatments on MSUConclusionAbout one third of MSU encounters were not AIS initially, including intracranial hemorrhage and stroke mimics. MSU can be utilized to provide pre-hospital treatments in emergent neurological conditions other than AIS. 相似文献
54.
55.
Fourteen consecutively referred, symptomatic patients with Waldenstrom's macroglobulinemia (ages 52-87 yr) have been treated with the 5-drug M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone). Three patients were previously treated and 11 patients were untreated. The majority of patients were symptomatic from hyperviscosity. All patients have responded to therapy. Two patients have achieved complete remissions and 12 patients partial remissions to date. None of the patients with symptomatic hyperviscosity has required plasmapheresis since therapy with the M-2 has been initiated. Lymphadenopathy, hepatosplenomegaly, and anemia have also responded to treatment. Follow-up data are limited, with survival from initiation of therapy with the M-2 ranging from 2+ to 35% mo (median 17+ mo) 2+-40+ mo from time of diagnosis). Combination chemotherapy for Waldenstrom's macroglobulinemia with the M-2 protocol appears to increase the response rate in patients with symptomatic disease. Further survival analysis will be carried out. 相似文献
56.
57.
58.
59.